Diabetes, Digestive, Kidney Extramural Research - Special Diabetes Program
Active
- Assistance listing
- 93.KT1
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Grant awards
- Not on record
Program facts
- Treasury account
-
- 75-0884-0-1-552
Program details come from SAM.gov Assistance Listings. Updated .
About this program
The National Institutes of Health (NIH), specifically the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), administers the Special Diabetes Program (CFDA 93.KT1), which funds extramural basic and clinical biomedical research addressing Type 1 Diabetes etiology, pathogenesis, prevention, diagnosis, treatment, and cure, with no recent grant opportunities currently posted.
The program supports fundamental and clinical studies investigating the mechanisms underlying Type 1 Diabetes and its complications. NIDDK operates the program on behalf of the Secretary of the Department of Health and Human Services in collaboration with multiple NIH Institutes and Centers and the CDC, informed by the Diabetes Mellitus Interagency Coordinating Committee. Funding flows to universities, colleges, medical, dental, and nursing schools, schools of public health, laboratories, hospitals, State and local health departments, and other public or private institutions, both non-profit and for-profit. Individuals with appropriate skills, knowledge, and resources may serve as Program Director or Principal Investigator. Small businesses qualify for SBIR and STTR awards under standard size and ownership criteria; STTR grants require partnership with a research institution.
The program predominantly funds Project Grants, with a smaller component supporting SBIR and STTR awards. Project Grant awards are reviewed and processed over 6 to 9 months; SBIR and STTR applications over approximately 7.5 months. All applications undergo peer review for scientific merit by an appropriate peer review panel and the National Diabetes and Digestive and Kidney Diseases Advisory Council. Approved applications compete for available funds on a merit basis.
The source does not report recent grant award data, portfolio concentration by funding agency, recent award magnitudes, or representative recent recipients. No open or recently posted grant opportunities are documented in the source.
Objective and description
- Objective
To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying Type 1 Diabetes and leads to improved preventions, diagnosis, treatment, and cure of Type 1 Diabetes. NIDDK administers the Spe
- Description
To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying Type 1 Diabetes and leads to improved preventions, diagnosis, treatment, and cure of Type 1 Diabetes. NIDDK administers the Special Statutory Funding Prgoram for Type 1 Diabetes Research or Special Diabetes Program on behalf of the Secretary of the Department of Health and Human Services, in collaboration with multiple NIH Institutes and Centers and the CDC, and with input from the Diabetes Mellitus Interagency Coordinating Committee. Specific programs areas of interest include fundamental and clinical studies including the etiology, pathogenesis, prevention, diagnosis, treatment and cure of Type 1 Diabetes and its complications.
Eligibility
- Applicant eligibility
Eligible Organizations: For non-SBIR/STTR awards, universities, colleges, medical, dental and nursing schools, schools of public health, laboratories, hospitals, State and local health departments, other public or private institutions, both non-profit and for-profit, and individuals who propose to establish, expand, and improve research activities in health sciences and related fields. Eligible Individuals (Program Director/Principal Investigator (PD/PI)): Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the PD(s)/PI(s) is invited to work with his/her organization to develop an application for support. SBIR and STTR grants can be awarded only to domestic small businesses that meet the following criteria: 1) Is independently owned and operated, is not dominant in the field of operation in which it is proposing, has a place of business in the United States (US) and operates primarily within the US or makes a significant contribution to the US economy, and is organized for profit; 2) Is (a) at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the US, or (b) for SBIR only, it must be a for-profit business concern that is at least 51% owned and controlled by another for-profit business concern that is at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the US. 3) Has, including its affiliates, an average number of employees for the preceding 12 months not exceeding 500, and meets the other regulatory requirements found in 13 C.F.R. Part 121. Business concerns are generally considered to be affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both. STTR grants which "partner" with a research institution in cooperative research and development. At least 40% of the project is to be performed by the small business concern and at least 30% by the research institution.
- Beneficiary eligibility
Health professionals, graduate students, health professional students, scientists, and researchers, any nonprofit or for-profit organization, company, or institution engaged in biomedical research. US-owned and operated small businesses and associated health professionals, scientists, and researchers, engaged in biomedical research. Program Director(s)/Principal Investigator(s): Although no degree of education is either specified or required, nearly all successful applicants have doctoral degrees in one of the sciences or professions.
- Uses of assistance
Health/Medical, Higher Education (includes Research): Project Grants provide funds for salaries, equipment, supplies, travel, and other expenses associated with scientific investigation relevant to program objectives. SBIR Phase I grants (of approximately 6-months duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of the Phase II application.
- Use restrictions
Specific Restrictions Determined at NOFO Level
How to apply
- Criteria for selecting proposals
The major elements in evaluating non-SBIR/STTR proposals include assessments of: (1) The scientific merit and general significance of the proposed study and its objectives; (2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technological innovation, originality, or societal importance of the proposed research; (5) the potential of the proposed research for commercial application; (6) the reasonableness of the budget requested for the work proposed; (7) the adequacy and suitability of the facilities and research environment; and (8) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment.
- Award procedure
Grant applications are reviewed initially for scientific merit by an appropriate peer review panel and by the National Diabetes and Digestive and Kidney Diseases Advisory Council composed of leaders in medical science, education, and public affairs. Approved applications will compete on a merit basis for available funds. Successful applicants are sent a Notice of Grant Award. All accepted SBIR/STTR applications are evaluated for scientific and technical merit by an appropriate scientific peer review panel and by a national advisory council or board. All applications receiving a priority score compete for available SBIR/STTR set-aside funds on the basis of scientific and technical merit and commercial potential of the proposed research, program relevance, and program balance among the areas of research. The successful applicant is sent a Notice of Grant Award.
- Time to approval or disapproval
Project Grants: From 6 to 9 months. SBIR/STTR applications: About 7-1/2 months.
- Renewals
Renewals are determined by competitive application and review. Extensions considered upon request.
- Appeals
A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page https://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-064.html.
Grant opportunities
Quick answers
What is Assistance Listing 93.KT1?
Assistance Listing 93.KT1 is Diabetes, Digestive, Kidney Extramural Research - Special Diabetes Program, a federal grant program run by National Institutes of Health (Department of Health and Human Services).
What is the CFDA number for Diabetes, Digestive, Kidney Extramural Research - Special Diabetes Program?
Its CFDA number is 93.KT1: Assistance Listing numbers were called CFDA numbers before 2018.
Are there open grant opportunities under 93.KT1?
1 listed opportunity under 93.KT1 is open or forecasted. The latest, Single Source Competition for Biostatistical and Coordinating Center Renewal of the NIDDK CLEAR Study Consortium (Closed-Loop and Education for Hypoglycemia Awareness Restoration) (U24- Resource-Related Research Project, Cooperative Agreements), was posted on November 18, 2026.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program